Search research articles
Contact Us
Filters
Showing results (521-530 of 548) with videos related to
Page
of 55
Sort By:
The International Journal of Neuropsychopharmacology
|
February 8, 2012
Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats
Jerome Mairesse, Viviana Silletti, Charlotte Laloux, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
November 1, 2019
Developmental abnormalities in cortical GABAergic system in mice lacking mGlu3 metabotropic glutamate receptors
Tiziana Imbriglio, Remy Verhaeghe, Katiuscia Martinello, et al.
Pharmacological Research
|
February 16, 2016
The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-ß1-42 oligomers in mice
Gian Marco Leggio, Maria Vincenza Catania, Daniela Puzzo, et al.
Current Neuropharmacology
|
April 8, 2025
The Potential Influence of Associated Antidepressants on the Pharmacokinetic Profile of Esketamine in Patients Affected by Treatment-resistant Depression
Marika Alborghetti, Luana Lionetto, Ginevra Lombardozzi, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
September 20, 2011
The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression
Filippo Caraci, Paolo Bosco, Maria Signorelli, et al.
Current Pharmaceutical Design
|
March 8, 2012
Targeting the cancer initiating cell: the ultimate target for cancer therapy
James A McCubrey, Linda S Steelman, Stephen L Abrams, et al.
Biochimica Et Biophysica Acta
|
September 11, 2016
Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer
James A McCubrey, Dariusz Rakus, Agnieszka Gizak, et al.
Oncotarget
|
June 17, 2014
GSK-3 as potential target for therapeutic intervention in cancer
James A McCubrey, Linda S Steelman, Fred E Bertrand, et al.
Molecular Neurobiology
|
January 7, 2023
Common and Rare Variants in TMEM175 Gene Concur to the Pathogenesis of Parkinson's Disease in Italian Patients
Nicole Piera Palomba, Giorgio Fortunato, Giuseppe Pepe, et al.
Oncotarget
|
December 22, 2016
Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells
James A McCubrey, Timothy L Fitzgerald, Li V Yang, et al.
Page
of 55
Search research articles
Search
Showing results (521-530 of 548) with videos related to
Sort By:
Page
of 55
The International Journal of Neuropsychopharmacology
|
February 8, 2012
Chronic agomelatine treatment corrects the abnormalities in the circadian rhythm of motor activity and sleep/wake cycle induced by prenatal restraint stress in adult rats
Jerome Mairesse, Viviana Silletti, Charlotte Laloux, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
November 1, 2019
Developmental abnormalities in cortical GABAergic system in mice lacking mGlu3 metabotropic glutamate receptors
Tiziana Imbriglio, Remy Verhaeghe, Katiuscia Martinello, et al.
Pharmacological Research
|
February 16, 2016
The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-ß1-42 oligomers in mice
Gian Marco Leggio, Maria Vincenza Catania, Daniela Puzzo, et al.
Current Neuropharmacology
|
April 8, 2025
The Potential Influence of Associated Antidepressants on the Pharmacokinetic Profile of Esketamine in Patients Affected by Treatment-resistant Depression
Marika Alborghetti, Luana Lionetto, Ginevra Lombardozzi, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
September 20, 2011
The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression
Filippo Caraci, Paolo Bosco, Maria Signorelli, et al.
Current Pharmaceutical Design
|
March 8, 2012
Targeting the cancer initiating cell: the ultimate target for cancer therapy
James A McCubrey, Linda S Steelman, Stephen L Abrams, et al.
Biochimica Et Biophysica Acta
|
September 11, 2016
Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer
James A McCubrey, Dariusz Rakus, Agnieszka Gizak, et al.
Oncotarget
|
June 17, 2014
GSK-3 as potential target for therapeutic intervention in cancer
James A McCubrey, Linda S Steelman, Fred E Bertrand, et al.
Molecular Neurobiology
|
January 7, 2023
Common and Rare Variants in TMEM175 Gene Concur to the Pathogenesis of Parkinson's Disease in Italian Patients
Nicole Piera Palomba, Giorgio Fortunato, Giuseppe Pepe, et al.
Oncotarget
|
December 22, 2016
Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells
James A McCubrey, Timothy L Fitzgerald, Li V Yang, et al.
Page
of 55